300 related articles for article (PubMed ID: 12368193)
1. Loss of p63 expression is associated with tumor progression in bladder cancer.
Urist MJ; Di Como CJ; Lu ML; Charytonowicz E; Verbel D; Crum CP; Ince TA; McKeon FD; Cordon-Cardo C
Am J Pathol; 2002 Oct; 161(4):1199-206. PubMed ID: 12368193
[TBL] [Abstract][Full Text] [Related]
2. Frequent alteration of p63 expression in human primary bladder carcinomas.
Park BJ; Lee SJ; Kim JI; Lee SJ; Lee CH; Chang SG; Park JH; Chi SG
Cancer Res; 2000 Jul; 60(13):3370-4. PubMed ID: 10910040
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions.
Nylander K; Coates PJ; Hall PA
Int J Cancer; 2000 Aug; 87(3):368-72. PubMed ID: 10897041
[TBL] [Abstract][Full Text] [Related]
4. Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms.
Koga F; Kawakami S; Kumagai J; Takizawa T; Ando N; Arai G; Kageyama Y; Kihara K
Br J Cancer; 2003 Mar; 88(5):740-7. PubMed ID: 12618884
[TBL] [Abstract][Full Text] [Related]
5. p63 gene expression study and early bladder carcinogenesis.
Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
7. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.
Karni-Schmidt O; Castillo-Martin M; Shen TH; Gladoun N; Domingo-Domenech J; Sanchez-Carbayo M; Li Y; Lowe S; Prives C; Cordon-Cardo C
Am J Pathol; 2011 Mar; 178(3):1350-60. PubMed ID: 21356385
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
9. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
10. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
[TBL] [Abstract][Full Text] [Related]
11. Expression of p63 and p73 in ameloblastomas.
Kumamoto H; Ohki K; Ooya K
J Oral Pathol Med; 2005 Apr; 34(4):220-6. PubMed ID: 15752257
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
DeYoung MP; Johannessen CM; Leong CO; Faquin W; Rocco JW; Ellisen LW
Cancer Res; 2006 Oct; 66(19):9362-8. PubMed ID: 17018588
[TBL] [Abstract][Full Text] [Related]
13. DeltaNp63 plays an anti-apoptotic role in ventral bladder development.
Cheng W; Jacobs WB; Zhang JJ; Moro A; Park JH; Kushida M; Qiu W; Mills AA; Kim PC
Development; 2006 Dec; 133(23):4783-92. PubMed ID: 17079275
[TBL] [Abstract][Full Text] [Related]
14. p63 expression profiles in human normal and tumor tissues.
Di Como CJ; Urist MJ; Babayan I; Drobnjak M; Hedvat CV; Teruya-Feldstein J; Pohar K; Hoos A; Cordon-Cardo C
Clin Cancer Res; 2002 Feb; 8(2):494-501. PubMed ID: 11839669
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications.
Maruya S; Kies MS; Williams M; Myers JN; Weber RS; Batsakis JG; El-Naggar AK
Hum Pathol; 2005 Jul; 36(7):821-7. PubMed ID: 16084953
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of p63 protein in human esophageal squamous cell carcinomas.
Hu H; Xia SH; Li AD; Xu X; Cai Y; Han YL; Wei F; Chen BS; Huang XP; Han YS; Zhang JW; Zhang X; Wu M; Wang MR
Int J Cancer; 2002 Dec; 102(6):580-3. PubMed ID: 12447998
[TBL] [Abstract][Full Text] [Related]
18. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations.
Westfall MD; Mays DJ; Sniezek JC; Pietenpol JA
Mol Cell Biol; 2003 Apr; 23(7):2264-76. PubMed ID: 12640112
[TBL] [Abstract][Full Text] [Related]
19. Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway.
Fukushima H; Koga F; Kawakami S; Fujii Y; Yoshida S; Ratovitski E; Trink B; Kihara K
Cancer Res; 2009 Dec; 69(24):9263-70. PubMed ID: 19934319
[TBL] [Abstract][Full Text] [Related]
20. p63: oncogene or tumor suppressor?
Mills AA
Curr Opin Genet Dev; 2006 Feb; 16(1):38-44. PubMed ID: 16359856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
